Metabolic and electrophysiological changes in the basal ganglia of transgenic Huntington's disease rats

被引:7
作者
Vlamings, Rinske [1 ,2 ,3 ,7 ]
Benazzouz, Adbelhamid [3 ]
Chetrit, Jonathan [3 ,4 ]
Janssen, Marcus L. F. [1 ,7 ]
Kozan, Ramazan [5 ]
Visser-Vandewalle, Veerle [2 ]
Steinbusch, Harry W. M. [1 ,7 ]
von Hoersten, Stephan [6 ]
Temel, Yasin [1 ,2 ,7 ]
机构
[1] Maastricht Univ, Med Ctr, Dept Neurosci, NL-6202 AZ Maastricht, Netherlands
[2] Maastricht Univ, Med Ctr, Dept Neurosurg, NL-6202 AZ Maastricht, Netherlands
[3] Univ Bordeaux, Inst Malad Neurodegenerat, CNRS, UMR 5293, Bordeaux, France
[4] Univ Sheffield, Dept Biomed Sci, Sheffield S10 2TN, S Yorkshire, England
[5] Bezmialem Vakif Univ, Fac Med, Dept Physiol, Istanbul, Turkey
[6] Univ Erlangen Nurnberg, Franz Penzoldt Ctr, Dept Expt Therapy, Nurnberg, Germany
[7] European Grad Sch Neurosci EURON, Maastricht, Netherlands
关键词
Huntington's disease; Basal ganglia; Transgenic rat; Cytochrome oxidase; PGC-1; alpha; Electrophysiology; GLOBUS-PALLIDUS STIMULATION; DEEP BRAIN-STIMULATION; SUBTHALAMIC NUCLEUS; NEURONAL-ACTIVITY; MODEL; NEURODEGENERATION; MOTOR; ABNORMALITIES; DYSFUNCTION; DOPAMINE;
D O I
10.1016/j.nbd.2012.07.006
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Huntington's disease (HD) is characterized by neuronal loss in the striatum, ultimately leading to an 'imbalance' in the electrical activity of the basal ganglia-thalamocortical circuits. To restore this 'imbalance' in HD patients, which is held responsible for (some) of the motor symptoms, different basal ganglia nuclei have been targeted for surgical therapies, such as ablative surgery and deep brain stimulation. However, evidence to target brain nuclei for surgical therapies in HD is lacking. We reasoned that a neuronal and metabolic mapping of the basal ganglia nuclei could identify a functional substrate for therapeutic interventions. Therefore, the aim of the present study was to investigate the metabolic and neuronal activity of basal ganglia nuclei in a transgenic rat model of HD (tgHD). Subjects were 10-12 month old tgHD rats and wildtype littermates. We examined the striatum, globus pallidus, entopeduncular nucleus, the subthalamic nucleus and substantia nigra at different levels. First, we determined the overall neuronal activity at a supracellular level, by cytochrome oxidase histochemistry. Secondly, we determined the subcellular metabolic activity, by immunohistochemistry for peroxisome proliferator-activated receptor-gamma transcription co-activator (PGC-1 alpha), a key player in the mitochondrial machinery. Finally, we performed extracellular single unit recordings in the nuclei to determine the cellular activity. In tgHD rats, optical density analysis showed a significantly increased cytochrome oxidase levels in the globus pallidus and subthalamic nucleus when compared to controls. PGC-1 alpha expression was only enhanced in the subthalamic nucleus and electrophysiological recordings revealed decreased firing frequency of the majority of the neurons in the globus pallidus and increased firing frequency of the majority of the neurons in the subthalamic nucleus. Altogether, our results suggest that the globus pallidus and subthalamic nucleus play a role in the neurobiology of HD and can be potential targets for therapeutic interventions. (c) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:488 / 494
页数:7
相关论文
共 42 条
  • [1] ABNORMALITIES OF STRIATAL PROJECTION NEURONS AND N-METHYL-D-ASPARTATE RECEPTORS IN PRESYMPTOMATIC HUNTINGTONS-DISEASE
    ALBIN, RL
    YOUNG, AB
    PENNEY, JB
    HANDELIN, B
    BALFOUR, R
    ANDERSON, KD
    MARKEL, DS
    TOURTELLOTTE, WW
    REINER, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (18) : 1293 - 1298
  • [2] Amelioration of behavioral deficits in a rat model of Huntington's disease by an excitotoxic lesion to the globus pallidus
    Ayalon, L
    Doron, R
    Weiner, I
    Joel, D
    [J]. EXPERIMENTAL NEUROLOGY, 2004, 186 (01) : 46 - 58
  • [3] DOPAMINE AND NORADRENALINE IN POSTMORTEM BRAIN IN HUNTINGTONS-DISEASE AND SCHIZOPHRENIC ILLNESS
    BIRD, ED
    SPOKES, EGS
    IVERSEN, LL
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1980, 61 : 63 - 73
  • [4] CHEMICAL PATHOLOGY OF HUNTINGTONS-DISEASE
    BIRD, ED
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1980, 20 : 533 - 551
  • [5] Progressive deterioration of reaction time performance and choreiform symptoms in a new Huntington's disease transgenic ratmodel
    Cao, Chunyan
    Temel, Yasin
    Blokland, Arjan
    Ozen, Hatice
    Steinbusch, Harry W. M.
    Vlamings, Rinske
    Nguyen, Huu Phuc
    von Hoersten, Stephan
    Schmitz, Christoph
    Visser-Vandewalle, Veerle
    [J]. BEHAVIOURAL BRAIN RESEARCH, 2006, 170 (02) : 257 - 261
  • [6] Ciarmiello A, 2006, J NUCL MED, V47, P215
  • [7] Transcriptional repression of PGC-α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration
    Cui, Libin
    Jeong, Hyunkyung
    Borovecki, Fran
    Parkhurst, Christopher N.
    Tanese, Naoko
    Krainc, Dimitri
    [J]. CELL, 2006, 127 (01) : 59 - 69
  • [8] GPi-DBS in Huntington's disease: Results on motor function and cognition in a 72-year-old case
    Fasano, Alfonso
    Mazzone, Paolo
    Piano, Carla
    Quaranta, Davide
    Soleti, Francesco
    Bentivoglio, Anna Rita
    [J]. MOVEMENT DISORDERS, 2008, 23 (09) : 1289 - 1293
  • [9] PGC-1 coactivators: inducible regulators of energy metabolism in health and disease
    Finck, BN
    Kelly, DP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (03) : 615 - 622
  • [10] The pattern of neurodegeneration in Huntington's disease:: A comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease
    Glass, M
    Dragunow, M
    Faull, RLM
    [J]. NEUROSCIENCE, 2000, 97 (03) : 505 - 519